Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 11/20 | 0.80 |
| ▸ | CPT1B | Q92523 | 10/20 | 0.80 |
| ▸ | CPT2 | P23786 | 7/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904665 | 0.89 | CPT1A (0.82) | CPT1ACPT1BCPT2LMNAMEN1 | |
| SCHEMBL3565094 | 0.89 | CPT1A (1.00) | CPT1ACPT1BCPT2PPARGPPARD | |
| SCHEMBL2900550 | 0.85 | CPT1A (1.00) | CPT1ACPT1BCPT2MEN1KMT2A | |
| SCHEMBL3568174 | 0.84 | CPT1A (0.75) | CPT1ACPT1BCPT2STAT3PPARG | |
| SCHEMBL3576367 | 0.81 | CPT1A (0.76) | CPT1ACPT1BCPT2HPGD | |
| SCHEMBL2898514 | 0.80 | CPT1A (0.82) | CPT1ACPT1BCPT2 | |
| SCHEMBL30016326 | 0.79 | CPT1A (0.82) | CPT1ACPT1BCPT2 | |
| SCHEMBL3570173 | 0.79 | CPT1A (0.82) | CPT1ACPT1BCPT2 | |
| SCHEMBL3577725 | 0.78 | CPT1A (0.75) | CPT1ACPT1BCPT2STAT3PPARG | |
| SCHEMBL2904529 | 0.76 | CPT1A (1.00) | CPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT1B 2/4885CPT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.